NYS SBDC Scientific Innovation Impact Award: Dr. Hanna Wollocko of Oxyvita
While working in emergency services and in hospital blood banks, Dr. Hanna Wollocko, Founder, President and CEO of Oxyvita, Inc., recognized the enormous needs and significant problems with blood transfusions. She and a group of professionals from the pharmaceutical and biotechnology fields founded Oxyvita in 2003 to work on developing an innovative blood substitute. The product is a polymeric hemoglobin solution, which is clinically useful as a blood substitute due to its oxygen carrying function, can dramatically reduce the need for blood donated by human donors and significantly reduce the risks associated with blood transfusions. Dr. Wollocko first consulted Business Advisor Don Dods at the Mid-Hudson SBDC in 2004 about financing to continue the research. He has worked intensely with Dr. Wollocko and her team to develop the product into a sustainable business that is ready to market. The business is now significantly advanced in preclinical trials and will be seeking to progress into clinical trials upon FDA approval. Oxyvita Inc. has developed a powder form of its transfusible hemoglobin based oxygen carrier. With its new paradigm in blood technology, the company has been awarded a $4.4 million contract with the US Department of the Navy to enable testing of OxyVita on large animals as a requirement in the last stages of seeking final FDA approval. As you can imagine, OxyVita has the potential to revolutionize trauma care.